Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jie Li, Siwen Chen, Hui Xue, Haoyi Wang, Tianwei Huang, Hongya Xie, Jiang He, Cai Ke, Zhaonan Yu & Bin Ni. (2022) Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. OncoTargets and Therapy 15, pages 571-584.
Read now
Read now
Articles from other publishers (41)
Joanna Moes-Sosnowska, Adam Szpechcinski & Joanna Chorostowska-Wynimko. (2024) Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Tumor Biology 46:s1, pages S309-S325.
Crossref
Crossref
T. Fulton-Ward & G. Middleton. (2023) The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. Annals of Oncology 34:12, pages 1113-1130.
Crossref
Crossref
Huiwen Qian, Chunqi Hou, Yi Zhang, Shundong Ji, Chongke Zhong, Juan Li, Qianqian Zhang, Jianan Huang, Chong Li & ChengJi. (2023) Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma. Cancer Genetics 278-279, pages 62-70.
Crossref
Crossref
Yanfeng Xi, Zhongyuan Bai, Sihang Gao, Jianghong Guo, Zhen Zhang, Hongling Zhang, Li Qu, Bing Xu, Weiwei Wang, Guangyu Shan, Wei Cui, Wenqi Bai & Xiaoyong Ji. (2023) Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology 149:11, pages 8573-8580.
Crossref
Crossref
Kana Watanabe, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara & Makoto Maemondo. (2023) Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers 15:17, pages 4231.
Crossref
Crossref
Federica Pezzuto, Véronique Hofman, Christophe Bontoux, Francesco Fortarezza, Francesca Lunardi, Fiorella Calabrese & Paul Hofman. (2023) The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?. Lung Cancer 181, pages 107249.
Crossref
Crossref
Makoto Nishio, Luis Paz-Ares, Martin Reck, Kazuhiko Nakagawa, Edward B. Garon, Sanjay Popat, Matteo Ceccarelli, Hillary T. Graham, Carla Visseren-Grul & Silvia Novello. (2023) RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. Clinical Lung Cancer 24:5, pages 415-428.
Crossref
Crossref
Miriam Grazia Ferrara, Lorenzo Belluomini, Annafrancesca Smimmo, Marco Sposito, Alice Avancini, Diana Giannarelli, Michele Milella, Sara Pilotto & Emilio Bria. (2023) Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology 184, pages 103929.
Crossref
Crossref
Haiyan Sun, Peng Ren, Yongzi Chen, Lan Lan, Zhuchen Yan, Yinli Yang, Bin Wang, Cong Wang, Yanwei Li, Ling Li, Yu Zhang, Yanyang Li, Zuolin Wang, Zhanyu Pan & Zhansheng Jiang. (2023) Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. BMC Cancer 23:1.
Crossref
Crossref
Wensheng Jiang, Huanqing Cheng, Lili Yu, Jie Zhang, Yihui Wang, Yun Liang, Feng Lou, Huina Wang & Shanbo Cao. (2022)
Mutation patterns and evolutionary action score of
TP53
enable identification of a patient population with poor prognosis in advanced non‐small cell lung cancer
. Cancer Medicine 12:6, pages 6649-6658.
Crossref
Crossref
Shidan Wang, Ruichen Rong, Donghan M. Yang, Junya Fujimoto, Justin A. Bishop, Shirley Yan, Ling Cai, Carmen Behrens, Lynne D. Berry, Clare Wilhelm, Dara Aisner, Lynette Sholl, Bruce E. Johnson, David J. Kwiatkowski, Ignacio I. Wistuba, Paul A. BunnJr.Jr., John Minna, Guanghua Xiao, Mark G. Kris & Yang Xie. (2023) Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. Journal of Clinical Investigation 133:2.
Crossref
Crossref
J. Machado-Rugolo, C.M. Baldavira, T.G. Prieto, E.H.R. Olivieri, A.T. Fabro, C.A. Rainho, E.C. Castelli, P.E.M. Ribolla, A.M. Ab'Saber, T. Takagaki, M.A. Nagai & V.L. Capelozzi. (2023) Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. Brazilian Journal of Medical and Biological Research 56.
Crossref
Crossref
Jing Fu, Yuyang Tong, Ziguang Xu, Yaonan Li, Ya Zhao, Tao Wang, Cuidan Li & Shundong Cang. (2023) Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy. Clinical Lung Cancer 24:1, pages 29-39.
Crossref
Crossref
Kai Shang, Hongxiang Huang, Yongkang Xu, Yangyang Liu, Zhihui Lu & Li Chen. (2022) Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation. BMC Cancer 22:1.
Crossref
Crossref
Ambritha Balasundaram & C. George Priya Doss. (2022) Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach. International Journal of Molecular Sciences 23:24, pages 15499.
Crossref
Crossref
Rashidi Dzul Keflee, Kok Hoong Leong, Satoshi Ogawa, Jerome Bignon, Mun Chiang Chan & Kin Weng Kong. (2022) Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer. Biochemical Pharmacology 205, pages 115262.
Crossref
Crossref
Bo Lan, Na Zhao, Kang Du & Baolang Leng. (2022) Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis. Oncology Letters 24:5.
Crossref
Crossref
Ji-Youn Sung, Dong-Won Park & Seung-Hyeun Lee. (2022) High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. Biomedicines 10:9, pages 2109.
Crossref
Crossref
Binliang Liu, Zongbi Yi, Yanfang Guan, Quchang Ouyang, Chunxiao Li, Xiuwen Guan, Dan Lv, Lixi Li, Jingtong Zhai, Haili Qian, Binghe Xu, Fei Ma & Yixin Zeng. (2022)
Molecular landscape of
TP53
mutations in breast cancer and their utility for predicting the response to
HER
‐targeted therapy in
HER2
amplification‐positive and
HER2
mutation‐positive amplification‐negative patients
. Cancer Medicine 11:14, pages 2767-2778.
Crossref
Crossref
Surui Liu, Jin Yu, Hui Zhang & Jie Liu. (2022) TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Frontiers in Oncology 12.
Crossref
Crossref
Matteo Canale, Kalliopi Andrikou, Ilaria Priano, Paola Cravero, Luigi Pasini, Milena Urbini, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte & Paola Ulivi. (2022) The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. Cancers 14:5, pages 1143.
Crossref
Crossref
Sixian Chen, Aizhen Fu, Yuan Lu, Wei Lu, Yongfeng Chen, Shuiqiang Hong, Suli Zhou, Tianmin Xiang, Zhenzhen Zhang & Yongguang Cai. (2022) Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma. BMC Genomics 23:1.
Crossref
Crossref
Jin Cao, Juan J Gu, Yichen Liang & Buhai Wang. (2022)
Evaluate the Prognosis of
MYC/TP53
Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
. Technology in Cancer Research & Treatment 21, pages 153303382211382.
Crossref
Crossref
Na Zhou, Man Jiang & Xiaochun Zhang. (2022) Benefits of precision medicine in lung cancer: experience from a single institution. Visualized Cancer Medicine 3, pages 4.
Crossref
Crossref
Yongchang Zhang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Lingli Liu, Qinqin Xu, Haiyan Yang, Wenjuan Jiang, Analyn Lizaso, Luting Qiu, Ting Hou, Jun Liu, Ling Peng & Nong Yang. (2021) Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. BMC Medicine 19:1.
Crossref
Crossref
Sangyong Jung, Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, Hyojeong Park, Hyeonjeong Lee, Chang-Min Choi, Young Hoon Sung, Jae Cheol Lee & Jin Kyung Rho. (2021) Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Scientific Reports 11:1.
Crossref
Crossref
Ruiting Lin, Ruilian Chen, Zhiqiang Chen, Leihao Hu, Wei Guo, Zexin Zhang, Lizhu Lin & Hanrui Chen. (2021) Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review. Frontiers in Oncology 11.
Crossref
Crossref
Kan Gong, Yi Yang, Huan Huang, Xunjie Kuang & Xueqin Yang. (2021)
HER2‑amplified metastatic lung adenocarcinoma responds to fourth‑line pyrotinib therapy: A case report
. Molecular and Clinical Oncology 15:4.
Crossref
Crossref
Yong Dong, Qijun Li, Qian MiaoDa Li. (2021) Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis. Medicine 100:25, pages e26450.
Crossref
Crossref
Yiming Zhao, Shuyuan Wang, Zhengyu Yang, Yu Dong, Yanan Wang, Lele Zhang, Hai Hu & Baohui Han. (2021) Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Valerio Gristina, Maria La Mantia, Antonio Galvano, Sofia Cutaia, Nadia Barraco, Marta Castiglia, Alessandro Perez, Marco Bono, Federica Iacono, Martina Greco, Katia Calcara, Valentina Calò, Sergio Rizzo, Lorena Incorvaia, Maria Chiara Lisanti, Giulia Santanelli, Delia Sardo, Sara Inguglia, Lavinia Insalaco, Luisa Castellana, Stefania Cusenza, Gianni Pantuso, Antonio Russo & Viviana Bazan. (2021) Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. Journal of Molecular Pathology 2:2, pages 173-196.
Crossref
Crossref
Wai-Kok Choong & Ting-Yi Sung. (2021) Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. iScience 24:6, pages 102522.
Crossref
Crossref
Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, Hong-Hong Yan, Hai-Yan Tu, Hua-Jun Chen, Bin-Chao Wang, Zhen Wang, Qing Zhou, Xu-Chao Zhang, Jian Su, Rui-Lian Chen, Yi-Long Wu & Jin-Ji Yang. (2021) Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). Clinical Lung Cancer 22:2, pages 100-109.e3.
Crossref
Crossref
Motohiro Tamiya, Kei Kunimasa, Kazumi Nishino, Shingo Matsumoto, Hayato Kawachi, Kika Kuno, Takako Inoue, Hanako Kuhara, Fumio Imamura, Koichi Goto & Toru Kumagai. (2020) Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Investigational New Drugs 39:1, pages 232-236.
Crossref
Crossref
Zyanya Lucia Zatarain-Barrón, Andrés F. Cardona, Diego Díaz-García, Rogelio Trejo Rosales, Leonardo Rojas, Graciela Cruz-Rico, Rebecca Nagy, Luis Cabrera, Carlos Vargas, Jennifer Saam, Feliciano Barrón & Oscar Arrieta. (2021) Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. Oncology 99:8, pages 539-546.
Crossref
Crossref
H. Blons, J.-B. Oudart, J.-P. Merlio, D. Debieuvre, F. de Fraipont, C. Audigier-Valette, F. Escande, S. Hominal, P.‐P. Bringuier, S. Fraboulet-Moreau, L. Ouafik, D. Moro-Sibilot, A. Lemoine, A Langlais, P. Missy, F. Morin, P.-J. Souquet, F. Barlesi, J. Cadranel & M. Beau‐Faller. (2021) PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer 151, pages 69-75.
Crossref
Crossref
Christi M. J. Steendam, G. D. Marijn Veerman, Melinda A. Pruis, Peggy Atmodimedjo, Marthe S. Paats, Cor van der Leest, Jan H. von der Thüsen, David C. Y. Yick, Esther Oomen-de Hoop, Stijn L. W. Koolen, Winand N. M. Dinjens, Ron H. N. van Schaik, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Hendrikus Jan Dubbink & Anne-Marie C. Dingemans. (2020) Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. Cancers 12:11, pages 3179.
Crossref
Crossref
Xiaoyun Zhou, Xiaohui Xu, Zhenhuan Tian, Wang-Yang Xu & Yushang Cui. (2020) Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing. Journal of Cancer Research and Clinical Oncology 146:9, pages 2277-2287.
Crossref
Crossref
Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Giuseppe Bronte, Elisa Chiadini, Vienna Ludovini, Alessandra Dubini, Maximilian Papi, Sara Baglivo, Nicoletta De Luigi, Alberto Verlicchi, Rita Chiari, Lorenza Landi, Giulio Metro, Marco Angelo Burgio, Lucio Crinò & Paola Ulivi. (2020) Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. Journal of Clinical Medicine 9:4, pages 1047.
Crossref
Crossref
Seonggyu Byeon, Jung Yong Hong, Jeeyun Lee, Do-Hyun Nam, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang & Seung Tae Kim. (2020) Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. Targeted Oncology 15:2, pages 185-192.
Crossref
Crossref
Julie A. Vendrell, Xavier Quantin, Isabelle Serre & Jérôme Solassol. (2020) Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Therapeutic Advances in Medical Oncology 12, pages 175883592097419.
Crossref
Crossref